{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T21:01:56Z","timestamp":1781125316469,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.radonc.2025.111211","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:15:04Z","timestamp":1760998504000},"page":"111211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Patterns of relapse and outcomes following Single-Fraction High-Dose-Rate brachytherapy monotherapy for Intermediate-Risk prostate cancer"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0398-9806","authenticated-orcid":false,"given":"Constanza","family":"Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayson","family":"Paragas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Souhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sioufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7570-2179","authenticated-orcid":false,"given":"James M.G.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Stroian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Duclos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111211_b0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2025.111211_b0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/01.ju.0000152556.53602.64","article-title":"Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis","volume":"173","author":"Horwitz","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2025.111211_b0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cncr.23139","article-title":"The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer","volume":"112","author":"Abramowitz","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111211_b0020","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0360-3016(02)03828-2","article-title":"How low is the alpha\/beta ratio for prostate cancer?","volume":"55","author":"Wang","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111211_b0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"van Leeuwen","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111211_b0030","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150957","article-title":"Alpha\/beta (\u03b1\/\u03b2) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost","volume":"89","author":"Boonstra","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2025.111211_b0035","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.brachy.2021.07.006","article-title":"Low dose rate brachytherapy for primary treatment of localized prostate cancer: a systemic review and executive summary of an evidence-based consensus statement","volume":"20","author":"King","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111211_b0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2011.07.005","article-title":"American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy","volume":"11","author":"Davis","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111211_b0045","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijrobp.2012.03.035","article-title":"High-dose-rate prostate brachytherapy consistently results in high quality dosimetry","volume":"85","author":"White","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111211_b0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1538-4721(02)00101-0","article-title":"HDR brachytherapy for localized prostate cancer: the view from radiobiological models","volume":"1","author":"King","year":"2002","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111211_b0055","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2013.10.015","article-title":"Monotherapeutic high-dose-rate brachytherapy for prostate cancer: a dose reduction trial","volume":"110","author":"Yoshioka","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111211_b0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijrobp.2010.02.013","article-title":"Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions","volume":"80","author":"Yoshioka","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111211_b0065","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.ijrobp.2011.04.031","article-title":"High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence","volume":"82","author":"Hoskin","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111211_b0070","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2012.07.004","article-title":"High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results","volume":"85","author":"Zamboglou","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111211_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110381","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy: a 9-year update","volume":"198","author":"Hudson","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111211_b0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111211_b0085","article-title":"NCCN Clinical Practice guidelines in Oncology (NCCN guidelines\u00ae): P\u201drostate","author":"Network","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111211_b0090","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.clon.2018.05.007","article-title":"Randomised phase II Feasibility Trial of Image-guided External Beam Radiotherapy with or without High Dose Rate Brachytherapy boost in men with Intermediate-risk Prostate Cancer (CCTG PR15\/ NCT01982786)","volume":"30","author":"Vigneault","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2025.111211_b0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brachy.2011.05.003","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results","volume":"11","author":"Prada","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111211_b0100","doi-asserted-by":"crossref","first-page":"533","DOI":"10.5114\/jcb.2020.101685","article-title":"High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses - 14 years of single-centre experience","volume":"12","author":"Soatti","year":"2020","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111211_b0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijrobp.2016.08.011","article-title":"Favorable Preliminary Outcomes for men with Low- and Intermediate-risk Prostate CancerTreated with 19-Gy Single-fraction High-dose-rate Brachytherapy","volume":"97","author":"Krauss","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111211_b0110","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.brachy.2018.06.002","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fractionof 20.5Gy for the treatment of localized prostate cancer: Toxicityand 6-year biochemical results","volume":"17","author":"Prada","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111211_b0115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results","volume":"119","author":"Prada","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111211_b0120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.radonc.2013.09.025","article-title":"High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity","volume":"110","author":"Hoskin","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111211_b0125","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.ijrobp.2010.09.006","article-title":"High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial","volume":"82","author":"Barkati","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111211_b0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","article-title":"Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer","volume":"124","author":"Hoskin","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111211_b0135","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ijrobp.2021.12.164","article-title":"Patterns of Prostate Cancer Recurrence after Brachytherapy Determined by Prostate-specific Membrane Antigen-Positron Emission Tomography and Computed Tomography Imaging","volume":"112","author":"Raman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111211_b0140","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0022-5347(05)66452-X","article-title":"Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?","volume":"165","author":"Amling","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2025.111211_b0145","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.1999.17.5.1499","article-title":"Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer","volume":"17","author":"Kattan","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:13:21Z","timestamp":1781122401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025052156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"alternative-id":["S0167814025052156"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111211","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of relapse and outcomes following Single-Fraction High-Dose-Rate brachytherapy monotherapy for Intermediate-Risk prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111211"}}